STOCK TITAN
  1. Home
  2. News
  3. NRXP

NRX Pharmaceuticals Inc - NRXP STOCK NEWS

Welcome to our dedicated news page for NRX Pharmaceuticals (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on NRX Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NRX Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NRX Pharmaceuticals's position in the market.

News
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) plans an underwritten public offering of common stock to raise capital for working capital, general corporate purposes, and debt repayment. The offering's completion is subject to market conditions, with EF Hutton LLC as the sole book-running manager.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.31%
Tags
offering
-
News
NRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024
Rhea-AI Summary
NRx Pharmaceuticals announced key updates including awarding founding shares in HOPE Therapeutics to shareholders, a dividend proposal, and progress towards manufacturing ketamine supplies. Dr. Javitt will present at the BIO CEO & Investor Conference with a focus on expanding ketamine offerings and digital therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
none
-
News
NRx Pharmaceuticals (Nasdaq:NRXP) to Launch HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) announces completion of initial manufacture of Ketamine for IV infusion, plans to file FDA New Drug Application for acute suicidality treatment, and initiates pre-IPO offering of shares for qualified investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
none
News
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW)
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) advances NRX-101 through registrational trials with a $5 million milestone payment from partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. The company remains eligible for up to $324 million in future milestones and double-digit royalties upon approval. The payment extends NRx's cash runway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
none
-
News
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report
Rhea-AI Summary
NRx Pharmaceuticals achieves enrollment completion for NRX-101 trial in suicidal treatment-resistant bipolar depression, partnering with Lotus Pharmaceutical for Asia Pacific market. Lotus reports a 45% increase in revenues. NRx anticipates trial readout in Q2, emphasizing the critical need for innovative treatments in mental health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.34%
Tags
earnings
-
News
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend/Royalty Coupon
Rhea-AI Summary
NRx Pharmaceuticals, Inc. announces the incorporation of HOPE Therapeutics, a biotechnology company dedicated to bringing NRX-100 (IV Ketamine), re-designated HTX-100, as a potentially lifesaving treatment option for patients with Suicidal Depression. The company, initially owned by NRx and its current shareholders, will file a New Drug Application (NDA) for HTX-100 in the first half of 2024, and is taking steps to gain a public listing. The shareholder meeting planned for February 7, 2024, is cancelled and will be rescheduled if necessary. The company aims to provide FDA-approved IV Ketamine in a diversion- and abuse-deterrent presentation, with plans for state-of-the-art patient and reimbursement support. NRx also expects to convene a shareholder meeting in the coming weeks to vote on the planned structure of the spin-out of Hope Therapeutics and the stock dividend.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.28%
Tags
dividends
News
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) has announced the completion of enrollment in its Phase 2b/3 study of NRX-101, a patented combination of the NMDA antagonist D-cycloserine and lurasidone, in Suicidal Treatment Resistant Bipolar Depression. The enrollment of 74 patients exceeded the original target of 70 patients, triggering a milestone payment from Alvogen, who will be responsible for further development and commercialization costs for this program. The primary efficacy endpoint is the reduction in depression as measured on the MADRS scale, with top-line results expected later this quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
clinical trial
-
News
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Receipt of Positive Nasdaq Listing Determination
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) has been granted a transfer of its listing to The Nasdaq Capital Market, subject to the company evidencing compliance with all applicable criteria for continued listing. The company aims to meet the market value of listed securities and the minimum bid price requirements by April 16, 2024. NRx is also working towards filing its first New Drug Application for NRX-100 (ketamine) for the treatment of acute suicidal depression and announcing top line results from its phase 2b/3 trial of NRX-101 (D-cycloserine/lurasidone) in the treatment of suicidal bipolar depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
News
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has received Qualified Infectious Disease Product (QIDP) and Fast Track designation from the US FDA for NRX-101 in the treatment of complicated urinary tract infections (cUTI) and pyelonephritis. These designations grant Priority Review and an additional 5 years of data-exclusivity to NRX-101. The FDA also granted NRX-101 Fast Track designation for cUTI, which allows for rolling submission of the Company's New Drug Application. The active antibiotic ingredient of NRX-101 is D-cycloserine (DCS) that was developed as an antibiotic in the 1950's and used worldwide for the treatment of tuberculosis. NRx is seeking partners for commercialization of NRX-101. The press release emphasizes the need for a new therapeutic life to DCS as an antibiotic due to the increased antibiotic resistance rendering standard treatments for UTI ineffective in many cases. The company is optimistic that NRX-101 will have a minimal tendency to disrupt the microbiome of the intestine and potentially lead to reduced risk of C. difficile infection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
clinical trial
News
NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) announced their selection to give the keynote address at the Sachs Neuroscience Innovation Forum on January 7, 2024, discussing the benefits and risks of ketamine in treating suicidal depression. They plan to file a New Drug Application for ketamine in 2024 in the US and EU, partnering with the Fondation FundaMental of Paris, FR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.48%
Tags
conferences
Stock NRXP logo
NRX Pharmaceuticals Inc

Nasdaq:NRXP

NRXP Rankings

#4972 Ranked by Market Cap
#4956 Ranked by Stock Gains
N/A Ranked by Dividends

NRXP Stock Data

49.00M
6.63M
30.04%
4.29%
4.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Delray Beach